BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A. Advances in the medical treatment of Cushing's syndrome. Lancet Diabetes Endocrinol 2019;7:300-12. [PMID: 30033041 DOI: 10.1016/S2213-8587(18)30155-4] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Pivonello R, Zacharieva S, Elenkova A, Tóth M, Shimon I, Stigliano A, Badiu C, Brue T, Georgescu CE, Tsagarakis S, Cohen F, Fleseriu M. Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pituitary 2022. [PMID: 36085339 DOI: 10.1007/s11102-022-01263-7] [Reference Citation Analysis]
2 Mccartney NK, Baker DE. Levoketoconazole. Hosp Pharm. [DOI: 10.1177/00185787221115368] [Reference Citation Analysis]
3 Vetrivel S, Zhang R, Engel M, Oßwald A, Watts D, Chen A, Wielockx B, Sbiera S, Reincke M, Riester A. Characterization of Adrenal miRNA-Based Dysregulations in Cushing’s Syndrome. IJMS 2022;23:7676. [DOI: 10.3390/ijms23147676] [Reference Citation Analysis]
4 Regazzo D, Mondin A, Scaroni C, Occhi G, Barbot M. The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas. Int J Mol Sci 2022;23:6469. [PMID: 35742910 DOI: 10.3390/ijms23126469] [Reference Citation Analysis]
5 Sabahi M, Shahbazi T, Maroufi SF, Vidal K, Recinos PF, Kshettry VR, Roser F, Adada B, Borghei-Razavi H. MRI-Negative Cushing's Disease: A Review on Therapeutic Management. World Neurosurg 2022;162:126-137.e1. [PMID: 35338018 DOI: 10.1016/j.wneu.2022.03.076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY. Clinical Biology of the Pituitary Adenoma. Endocr Rev 2022:bnac010. [PMID: 35395078 DOI: 10.1210/endrev/bnac010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Vega-beyhart A, Laguna-moreno J, Díaz-catalán D, Boswell L, Mora M, Halperin I, Casals G, Hanzu FA. Ketoconazole- and Metyrapone-Induced Reductions on Urinary Steroid Metabolites Alter the Urinary Free Cortisol Immunoassay Reliability in Cushing Syndrome. Front Endocrinol 2022;13:833644. [DOI: 10.3389/fendo.2022.833644] [Reference Citation Analysis]
8 Mercera K, Mellin M, Mercera B, Elk C. Suspected hyperadrenocorticism in an Atlantic bottlenose dolphin ( Tursiops truncatus ): Diagnostic approach and treatment with ketoconazole. Vet Record Case Reports. [DOI: 10.1002/vrc2.271] [Reference Citation Analysis]
9 Voellger B, Zhang Z, Benzel J, Wang J, Lei T, Nimsky C, Bartsch JW. Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review. J Clin Med 2021;11:124. [PMID: 35011868 DOI: 10.3390/jcm11010124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Favero V, Cremaschi A, Falchetti A, Gaudio A, Gennari L, Scillitani A, Vescini F, Morelli V, Aresta C, Chiodini I. Management and Medical Therapy of Mild Hypercortisolism. Int J Mol Sci 2021;22:11521. [PMID: 34768949 DOI: 10.3390/ijms222111521] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Rabhi N, Desevin K, Cortez BN, Hekman R, Lin JZ, Emili A, Farmer SR. The cyclin dependent kinase inhibitor Roscovitine prevents diet-induced metabolic disruption in obese mice. Sci Rep 2021;11:20365. [PMID: 34645915 DOI: 10.1038/s41598-021-99871-z] [Reference Citation Analysis]
12 Fekri Azgomi H, Hahn JO, Faghih RT. Closed-Loop Fuzzy Energy Regulation in Patients With Hypercortisolism via Inhibitory and Excitatory Intermittent Actuation. Front Neurosci 2021;15:695975. [PMID: 34434085 DOI: 10.3389/fnins.2021.695975] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Lines KE, Filippakopoulos P, Stevenson M, Müller S, Lockstone HE, Wright B, Knapp S, Buck D, Bountra C, Thakker RV. Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells. Endocr Relat Cancer 2020;27:163-74. [PMID: 31935194 DOI: 10.1530/ERC-19-0448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Pivonello R, Bancos I, Feelders RA, Kargi AY, Kerr JM, Gordon MB, Mariash CN, Terzolo M, Ellison N, Moraitis AG. Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. Front Endocrinol (Lausanne) 2021;12:662865. [PMID: 34335465 DOI: 10.3389/fendo.2021.662865] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
15 Miceli DD, Zelarayán GS, García JD, Fernández V, Ferraris S. Diabetes mellitus remission in a cat with hyperadrenocorticism after cabergoline treatment. JFMS Open Rep 2021;7:20551169211029896. [PMID: 34345435 DOI: 10.1177/20551169211029896] [Reference Citation Analysis]
16 Rai A, Das L, Mukherjee KK, Dhandapani S, Tripathi M, Ahuja CK, Radotra BD, Dutta P. Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas. Front Endocrinol (Lausanne) 2021;12:708111. [PMID: 34295309 DOI: 10.3389/fendo.2021.708111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Pivonello R, Elenkova A, Fleseriu M, Feelders RA, Witek P, Greenman Y, Geer EB, Perotti P, Saiegh L, Cohen F, Arnaldi G. Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. Front Endocrinol (Lausanne) 2021;12:595894. [PMID: 33897615 DOI: 10.3389/fendo.2021.595894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Castinetti F, Nieman LK, Reincke M, Newell-Price J. Approach to the Patient Treated with Steroidogenesis Inhibitors. J Clin Endocrinol Metab 2021;106:2114-23. [PMID: 33675650 DOI: 10.1210/clinem/dgab122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
19 Gao L, Liu L, Shi L, Luo Y, Wang Z, Guo X, Xing B. Dynamic changes of views on the brain changes of Cushing's syndrome using different computer-assisted tool. Rev Endocr Metab Disord 2020;21:185-200. [PMID: 31974674 DOI: 10.1007/s11154-020-09540-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Chang M, Yang C, Bao X, Wang R. Genetic and Epigenetic Causes of Pituitary Adenomas. Front Endocrinol (Lausanne) 2020;11:596554. [PMID: 33574795 DOI: 10.3389/fendo.2020.596554] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
21 Zhao Y, Liang W, Cai F, Wu Q, Wang Y. Fluconazole for Hypercortisolism in Cushing's Disease: A Case Report and Literature Review. Front Endocrinol (Lausanne) 2020;11:608886. [PMID: 33391186 DOI: 10.3389/fendo.2020.608886] [Reference Citation Analysis]
22 Pivonello R, Ferrigno R, De Martino MC, Simeoli C, Di Paola N, Pivonello C, Barba L, Negri M, De Angelis C, Colao A. Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. Front Endocrinol (Lausanne) 2020;11:648. [PMID: 33363514 DOI: 10.3389/fendo.2020.00648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
23 Geer EB, Salvatori R, Elenkova A, Fleseriu M, Pivonello R, Witek P, Feelders RA, Bex M, Borresen SW, Puglisi S, Biller BMK, Cohen F, Pecori Giraldi F. Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. Pituitary 2021;24:104-15. [PMID: 33216275 DOI: 10.1007/s11102-020-01103-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
24 Fontaine-Sylvestre C, Létourneau-Guillon L, Moumdjian RA, Berthelet F, Lacroix A. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease. Pituitary 2021;24:207-15. [PMID: 33074401 DOI: 10.1007/s11102-020-01097-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
25 Beretta F, Dassie F, Parolin M, Boscari F, Barbot M, Busetto L, Mioni R, De Carlo E, Scaroni C, Fallo F, Vettor R, Maffei P. Practical Considerations for the Management of Cushing's Disease and COVID-19: A Case Report. Front Endocrinol (Lausanne) 2020;11:554. [PMID: 33071957 DOI: 10.3389/fendo.2020.00554] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
26 Barbot M, Regazzo D, Mondin A, Zilio M, Lizzul L, Zaninotto M, Plebani M, Arnaldi G, Ceccato F, Scaroni C. Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Pituitary 2020;23:534-42. [PMID: 32524277 DOI: 10.1007/s11102-020-01055-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
27 Grossman A. The sinister side of Cushing's therapy. The Lancet Diabetes & Endocrinology 2019;7:822-3. [DOI: 10.1016/s2213-8587(19)30312-2] [Reference Citation Analysis]
28 Tonsing-Carter E, Hernandez KM, Kim CR, Harkless RV, Oh A, Bowie KR, West-Szymanski DC, Betancourt-Ponce MA, Green BD, Lastra RR, Fleming GF, Chandarlapaty S, Conzen SD. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. Breast Cancer Res 2019;21:82. [PMID: 31340854 DOI: 10.1186/s13058-019-1164-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
29 Guarda FJ, Findling J, Yuen KCJ, Fleseriu M, Nachtigall LB. Mifepristone Increases Thyroid Hormone Requirements in Patients With Central Hypothyroidism: A Multicenter Study. J Endocr Soc 2019;3:1707-14. [PMID: 31528830 DOI: 10.1210/js.2019-00188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
30 Barbot M, Ceccato F, Scaroni C. The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome. Front Endocrinol (Lausanne) 2019;10:321. [PMID: 31164868 DOI: 10.3389/fendo.2019.00321] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]